Literature DB >> 17714220

Azoospermia in a renal transplant recipient during sirolimus (rapamycin) treatment.

J Skrzypek1, W Krause.   

Abstract

Sirolimus is used as a powerful immunosuppressant drug in patients after organ transplantation. It was shown to block spermatogenesis by interrupting the stem cell factor/c-kit system. Oligozoospermia was shown in single patients. In addition, a decrease of testosterone and an increase of gonadotropin levels were observed. We report on a young patient who showed azoospermia during the treatment with sirolimus after renal transplantation. After changing the immunosuppression to tacrolimus, spermatogenesis of the patient recovered. Five months after cessation of the treatment with sirolimus, a sperm concentration of 8 x 10(6) ml(-1) was found. Depression of spermatogenesis is an important side effect in younger men who aspire paternity, so that waiving of sirolimus is advisable in these patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17714220     DOI: 10.1111/j.1439-0272.2007.00787.x

Source DB:  PubMed          Journal:  Andrologia        ISSN: 0303-4569            Impact factor:   2.775


  17 in total

Review 1.  Adult somatic cells to the rescue: nuclear reprogramming and the dispensability of gonadal germ cells.

Authors:  Charles A Easley; David R Latov; Calvin R Simerly; Gerald Schatten
Journal:  Fertil Steril       Date:  2014-01       Impact factor: 7.329

Review 2.  Mammalian target of rapamycin (mTOR): a central regulator of male fertility?

Authors:  Tito T Jesus; Pedro F Oliveira; Mário Sousa; C Yan Cheng; Marco G Alves
Journal:  Crit Rev Biochem Mol Biol       Date:  2017-01-26       Impact factor: 8.250

3.  Gonadal dysfunction and infertility in kidney transplant patients receiving sirolimus.

Authors:  Yousef Boobes; Bassam Bernieh; Hussein Saadi; M Raafat Al Hakim; Samra Abouchacra
Journal:  Int Urol Nephrol       Date:  2009-09-23       Impact factor: 2.370

4.  Why men age faster but reproduce longer than women: mTOR and evolutionary perspectives.

Authors:  Mikhail V Blagosklonny
Journal:  Aging (Albany NY)       Date:  2010-05       Impact factor: 5.682

Review 5.  [Value of targeted treatment for testicular cancer: from molecular approaches to clinical possibilities].

Authors:  A Martinschek; C G Ruf; C Sparwasser; H U Schmelz
Journal:  Urologe A       Date:  2008-10       Impact factor: 0.639

6.  [Rictor/mTORC2 regulates blood-testis barrier and spermatogenesis in mice].

Authors:  He-Ling Dong; Hong-Yuan Wu; You Fu; Meng Dai; Xiao-Chun Bai; Hong Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-10-20

Review 7.  Stem cell therapeutic possibilities: future therapeutic options for male-factor and female-factor infertility?

Authors:  Charles A Easley; Calvin R Simerly; Gerald Schatten
Journal:  Reprod Biomed Online       Date:  2013-03-26       Impact factor: 3.828

8.  Metformin and sex: Why suppression of aging may be harmful to young male mice.

Authors:  Mikhail V Blagosklonny
Journal:  Aging (Albany NY)       Date:  2010-12       Impact factor: 5.682

9.  Why the disposable soma theory cannot explain why women live longer and why we age.

Authors:  Mikhail V Blagosklonny
Journal:  Aging (Albany NY)       Date:  2010-12       Impact factor: 5.682

10.  Big mice die young but large animals live longer.

Authors:  Mikhail V Blagosklonny
Journal:  Aging (Albany NY)       Date:  2013-04       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.